Meningitis Outbreak is Changing the Rules
The recent fungal meningitis outbreak which has affected 19 states, including Texas, shines a blaring light on what some call “insufficient methods” used by the American health care system to regulate compounding pharmacies. According to a report by Yahoo News, Congressional officials, in cooperation with the U.S Food and Drug Administration (FDA), are looking to draft legislation in an attempt to prevent future outbreaks.
Senate Promises Regulatory Changes for Pharmacies
- According to reports, Senator Tom Harkin of the committee of the Health, Education, Labor and Pensions (HELP), and Senator Pat Roberts, committee member, both assured the public that changes will be made in regulations to help ensure the safety of products produced at compounding pharmacies.
- Senator Mike Enzi, a HELP committee member, promised intense scrutiny into any company involved in the meningitis outbreak.
- The FDA is requesting stricter authority over compounding pharmacies. Margaret Hamburg, FDA Commissioner, stated that she “didn’t know of any one action the FDA could have taken with current legislation in place to prevent the errors that lead to the fungal meningitis outbreak.”
- The U.S Centers for Disease Control and Prevention continue to urge any patient who has received the Methylprednisolone Acetate injection to consult their health care provider and to be cautious of any signs of symptoms.
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division has extensive knowledge and resources in order to represent our clients efficiently and aggressively.
If you or someone you love contracted fungal meningitis after being injected with Methylprednisolone Acetate produced at New England Compounding Pharmacy, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.